一分钟看懂
这是一项关于非小细胞肺癌的III 期研究，登记的药物或干预包括Pumitamig；Durvalumab，当前状态为招募中。登记地点显示中国北京、重庆、福州、汕头等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Pumitamig；Durvalumab · III 期
登记条件中文摘要
年龄范围：18岁及以上
登记的基本范围为不限性别，年龄18岁及以上；以下仅摘录8项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出6项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Beijing Cancer hospital · 北京
- Chongqing University Cancer Hospital · 重庆
- Fujian Cancer Hospital · 福州
- Cancer Hospital of Shantou University Medical College · 汕头
- Peking University Shenzhen Hospital · 深圳
- Local Institution - 0249 · 郑州
- Jingzhou First People's Hospital · Jingzhou
- The Central Hospital of Wuhan · 武汉
- Local Institution - 0813 · 武汉
- Local Institution - 0489 · 长沙
- The First Affiliated Hospital of Soochow University · 苏州
- The Second Affiliated Hospital of Nanchang University · 南昌
- Local Institution - 0242 · 沈阳
- The Second Affiliated Hospital of Xi'an Jiaotong University · 西安
- Local Institution - 0564 · 西安
- Qilu Hospital of Shandong University · 济南
- Shandong Cancer Hospital · 济南
- Local Institution - 0248 · 上海
- Shanxi Cancer Hospital · 太原
- Sichuan Cancer hospital · 成都
- Local Institution - 0440 · 成都
- The second Affiliated Hospital of College of Medicine, Zhejiang University · 杭州
- Zhejiang Cancer Hospital · 杭州
- Taizhou Hospital Of Zhejiang Province · 临海
- Sun Yat-sen University Cancer Center · 广州
- Local Institution - 0537 · 上海
入选条件原文摘录
以下为摘录，请打开原始登记查看完整入排标准。
- * Participants must have a histologically- or cytologically-confirmed diagnoses of non-small cell lung cancer (NSCLC) with unresectable Stage III disease.
- * Participants must have received at least 2 cycles of platinum-based concurrent chemoradiotherapy (a total dose of radiation of at least 54 Gy).
- * Participants must have no progressive disease (PD) following treatment with concurrent chemoradiotherapy (CCRT).
- * Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 or 1.
- Exclusion Criteria
- * Participants with non-squamous histology must not have documented Epidermal Growth Factor Receptor (EGFR) and anaplastic lymphoma kinase (ALK) rearrangements.
- * Participants must not have an active autoimmune disease.
- * Participants must not have significant cardiovascular impairment such as uncontrolled hypertension (despite optimal medical treatment), congestive heart failure, active coronary disease (within 6 months prior to randomization), ventricular arrhythmias, major thrombotic or embolic events or major hemorrhagic events within 6 months prior to randomization, or significant risk of pulmonary hemorrhage.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07361497；登记信息更新于 2026-09-30；本站同步于 2026-10-08，中国中心当前名额未经人工确认。